乌鸦传媒

MedpageToday
ASCO > Bladder Cancer

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

<乌鸦传媒 class="mpt-content-deck">鈥� An ASCO Reading Room selection
Uttam Satyal, PhD, Henkel Valentine, PhD, David Liu, MD, MS, Michael Slifker, PhD, Costas D. Lallas, MD, Edouard J. Trabulsi, MD, Laura Bukavina, MD, MPH, MSc, Lauren Szeto, MD, Jean H. Hoffman-Censits, MD, Kent W. Mouw, MD, PhD, Bishoy M. Faltas, MD, Petros Grivas, MD, PhD, Ilsiya Ibragimova, PhD, Sima P. Porten, MD, MPH, Eliezer M. Van Allen, MD, Daniel M. Geynisman, MD, Daniel C. Parker, MD, John P. O'Neill, MD, Johnathan Drevik, MD, Sarah S. Christianson, MD, Serge Ginzburg, MD, Andres F. Correa, MD, Robert G. Uzzo, MD, MBA, Eric A. Ross, PhD, ScM, Matthew R. Zibelman, MD, Pooja Ghatalia, MD, Elizabeth R. Plimack, MD, Alexander Kutikov, MD, and Philip H. Abbosh, MD, PhD
JCO Precision Oncology

This Reading Room is a collaboration between 乌鸦传媒庐 and:

Medpage Today
Below is the abstract of the article.
Read the full article PDF by clicking here
or on the link below.

Purpose

There is significant interest in identifying complete responders to neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) to potentially avoid removal of a pathologically benign bladder. However, clinical restaging after NAC is highly inaccurate. The objective of this study was to develop a next-generation sequencing–based molecular assay using urine to enhance clinical staging of patients with bladder cancer.

Methods

Urine samples from 20 and 44 patients with bladder cancer undergoing RC were prospectively collected for retrospective analysis for molecular correlate analysis from two clinical trials, respectively. The first cohort was used to benchmark the assay, and the second was used to determine the performance characteristics of the test as it correlates to responder status as measured by pathologic examination.

Results

First, to benchmark the assay, known mutations identified in the tissue (MT) of patients from the Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin trial (ClinicalTrials.gov identifier: , n = 16) and a cohort from University of California-San Francisco (n = 4) were cross referenced against mutation profiles from urine (MU). We then determined the correlation between MU persistence and residual disease in pre-RC urine samples from a second prospective clinical trial (The pT0 trial; ClinicalTrials.gov identifier: ). Residual MU status correlated strongly with residual disease status (pT0 trial, n=44; P=0.0092) when MU from urine supernatant and urine pellet were assessed separately and analyzed in tandem. The sensitivity, specificity, PPV, and NPV were 91%, 50%, 86%, and 63% respectively, with an overall accuracy of 82% for this second cohort.

Conclusion

MU are representative of MT and thus can be used to enhance clinical staging of urothelial carcinoma. Urine biopsy may be used as a reliable tool that can be further developed to identify complete response to NAC in anticipation of safe RC avoidance.

Read an interview about the study here and expert commentary about it here.

Read the full article

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

Primary Source

JCO Precision Oncology

Source Reference:

ASCO Publications Corner

ASCO Publications Corner